The name printed on a laboratory test does not establish that it measures every related analogue accurately. A routine IGF-1 result should not be treated as a validated LR3 exposure meter without evidence about that assay.
A research paper developing an LR3-specific ELISA used antibodies chosen to distinguish the analogue from native IGFs and evaluated the method in animal plasma. That work illustrates why specificity and interference need to be examined rather than assumed.
Three different questions can be confused
One question is how much endogenous IGF-1 is present. Another is whether an administered analogue is detected. A third is whether the reported signal accurately quantifies that analogue in the relevant sample. A test may answer one without answering the others.
The paper does not demonstrate that every modern clinical assay fails to detect LR3, nor that every assay detects it. It establishes the need for method-specific evidence. Claims in either direction require the laboratory's actual assay information.
A result also cannot independently identify the contents of a vial. The patient's measurement and the material's identity belong to separate investigations, even if both involve the same hormone family.
For a clinician or laboratory specialist, useful questions include the test's intended analyte, documented cross-reactivity, sample preparation and relevant interference data. For a general reader, the important action is to avoid treating an unexplained number as permission to adjust a research product.
This article provides no target range or self-monitoring protocol. It also does not endorse deliberate exposure as a way to test product authenticity.
The larger lesson is that measurement must be validated for the question being asked. “IGF-1” on a report and “IGF-1 LR3” on a catalog page share words, but that shared wording is not an analytical validation. The actual test's capabilities need to be established by a qualified laboratory professional.